Dihydropyrimidine dehydrogenase testing: From Pharmacogenomics to Equitable Practice
This commentary on a cohort study of patients with uncommon DPYD variants resulting in increased toxicities highlights the importance of expanding the current DPYD testing profile, the limitations of current testing, and the critical need to consider patients of African ancestry who can carry rare yet extremely toxic DPYD variants.
Authors
- Raghav Sundar (ORCID: https://orcid.org/0000-0001-9423-1368)
- Jacquelyne Gaddy (ORCID: https://orcid.org/0000-0003-1477-6136)
- Pamela L. Kunz (ORCID: https://orcid.org/0000-0003-1613-3919)
Institutions
- Yale Cancer Center (US)
- Yale University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-06-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0952
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00